Common Stock, $0.001 par value per share
- Symbol
- INSP
- Exchange
- NYSE
- Classification
- COMMON
- Status
- Current
Current Report · Items 5.02, 9.01 · 8-K
Inspire Medical Systems, Inc.
INSPNYSEEQUITYCurrent
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On July 16, 2026, Casey Tansey, a member of the Board of Directors (the “Board”) of Inspire Medical Systems, Inc.…
Press release in this filing
Inspire Medical Systems, Inc. Announces Retirement of Casey M. Tansey from its Board of Directors →Company context
Inspire is a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea. Inspire’s proprietary Inspire therapy is the first FDA, EU MDR and PDMA-approved neurostimulation technology of its kind that provides a safe and effective treatment for moderate to severe obstructive sleep apnea. For additional information about Inspire, please visit www.inspiresleep.com.
Current securities
Registered securities in this filing
INSPIRE MEDICAL SYSTEMS, INC. · 8-K · Filed 2026-07-22
Disclosure sections
Item 5.02Item 5.02 - Departure/Election of Directors
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On July 16, 2026, Casey Tansey, a member of the Board of Directors (the “Board”) of Inspire Medical Systems, Inc. (the “Company”), notified the Company of his decision to retire from the Board (and the committees on which he serves) and not stand for re-election at the Company’s 2027 Annual Meeting of Stockholders (the “2027 Annual Meeting”). Mr. Tansey’s retirement will become effective July 30, 2026. Mr. Tansey’s decision to retire and not stand for re-election was not the result of any disagreement with the Company or any matter relating to the Company’s operation, policies or practices.